TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29145824

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (elderly subgroup)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SVV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CVP
Number of subjects: 120
Study: 26321318

Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg orally, twice daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23542954

Group type: EXPERIMENTAL
Intervention: Survivorship Intervention (SI)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 126
Study: 21346166

Group type: EXPERIMENTAL
Intervention: Interactive animation video
Number of subjects: 211

Group type: COMPARATOR
Intervention: No video
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study: 18277878

Group type: EXPERIMENTAL
Intervention: Intensive group training protocol (exercise therapy, back school, behavioral principles)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care physiotherapy (guideline group)
Number of subjects: 114
Study: 16547634

Group type: EXPERIMENTAL
Intervention: Betamethasone (8 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (8 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14762840

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) used in 21 patients (Group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous clamping alone used in 21 patients (Group B)
Number of subjects: 42
Study: 11712620

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 78
Study: 9225527

Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison between halothane and isoflurane
Number of subjects: 32
Study: 8356591

Group type: EXPERIMENTAL
Intervention: TMP (160 mg)‐SMX (800 mg) twice daily three days per week (group B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TMP (160 mg)‐SMX (800 mg) twice daily seven days per week (group C)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 58
Study: 3306440

Group type: EXPERIMENTAL
Intervention: Caroverine (120 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meprobamate (2,400 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caroverine (2.5-5.0 mg/kg, infusional application)
Number of subjects: 0
Study: 30304749

Group type: EXPERIMENTAL
Intervention: Commercially available formula diet supplemented with oats fibers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group received a comparably restricted diet (approx. 1000 kcal/d)
Number of subjects: 36
Study: 27432604

Group type: EXPERIMENTAL
Intervention: Surotomycin 125 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times daily
Number of subjects: 0
Study: 23894101

Group type: EXPERIMENTAL
Intervention: ED+/MR-
Number of subjects: 238
Study: 22893770

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 162

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Rescue antiemetics
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Relative weight gain
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Summary score of postoperative symptoms
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Stress coping capacity
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 162
Study: 20541180

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 36

Group type: COMPARATOR
Intervention: Progressive muscle relaxation plus self-instruction to postpone worrying
Number of subjects: 36
Study: 18987098

Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily, mean dose 24 mg)
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study: 15816793

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/day in week 1, 16 mg/day in week 2, 24 mg/day in week 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ondansetron and Placebo
Number of subjects: 30
Study: 12873937

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane inhaled anesthesia
Number of subjects: 40
Study: 11176472

Group type: EXPERIMENTAL
Intervention: 5 mg bethanechol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22
Study: 9287928

Group type: EXPERIMENTAL
Intervention: Ventilation tubes placed antero-superiorly
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ventilation tubes placed antero-inferiorly
Number of subjects: 106
Study: 8281565

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (no-gum)
Number of subjects: 165
Study: 3557757

Group type: EXPERIMENTAL
Intervention: Cephradine 2 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g
Number of subjects: 40
Study: 30979507

Group type: EXPERIMENTAL
Intervention: PEEP-ZEEP in volume-controlled mode
Number of subjects: 19

Group type: COMPARATOR
Intervention: PEEP-ZEEP in pressure-controlled mode
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MCC application
Number of subjects: 19
Study: 29461411

Group type: EXPERIMENTAL
Intervention: Loco First (n = 50)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Object First (n = 48)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (CON) (n = 42)
Number of subjects: 140
Study: 28623425

Group type: EXPERIMENTAL
Intervention: 20-week high-intensity strength and sprint training program (EX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 72
Study: 25889522

Group type: EXPERIMENTAL
Intervention: IV inoculation with 50 PfSPZ
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IV inoculation with 200 PfSPZ
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IV inoculation with 800 PfSPZ
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IV inoculation with 3,200 PfSPZ
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Direct venous inoculation with 3,200 PfSPZ
Number of subjects: 18
Study: 23211012

Group type: EXPERIMENTAL
Intervention: 0.12% CHX + 0.05% CPC (test-group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo-solution (placebo-group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both decontamination procedures
Number of subjects: 30
Study: 20215961

Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 19734766

Group type: EXPERIMENTAL
Intervention: Tunnelled intravitreal injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Straight intravitreal injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17392720

Group type: EXPERIMENTAL
Intervention: Five-drug cocktail (Inje cocktail)
Number of subjects: 12
Study: 15042543

Group type: EXPERIMENTAL
Intervention: Iron dextran, 1,000 mg IV
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline IV (placebo)
Number of subjects: 25
Study: 11556875

Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11717931

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine Zeng Sheng Ping for severe dysplasia
Number of subjects: 9336

Group type: EXPERIMENTAL
Intervention: Tablets of riboflavin Calcium for mild dysplasia
Number of subjects: 9336

Group type: COMPARATOR
Intervention: Placebo for control group
Number of subjects: 9336
Study: 10150222

Group type: EXPERIMENTAL
Intervention: Nisoldipine once daily (up to 20 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nisoldipine twice daily (up to 20 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment (before and after nisoldipine)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nisoldipine once daily
Number of subjects: 33
Study: 3138906

Group type: EXPERIMENTAL
Intervention: High fat intake
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low fat intake
Number of subjects: 16
Study: 30817599

Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 43
Study: 29187151

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2.5 μg/kg (group D)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral ketamine 6 mg/kg (group K)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg and oral ketamine 3 mg/kg (group DK)
Number of subjects: 135
Study: 25924803

Group type: EXPERIMENTAL
Intervention: Corticosteroids (1 mg/kg/day i.v. methylprednisolone intraoperatively and at postoperative days 1-5)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 23739650

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/simvastatin 20 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 68
Study: 21763461

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouth rinse
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Listerine mouth rinse
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4% Tulsi extract mouth rinse
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of all three mouth rinses
Number of subjects: 45
Study: 19353707

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 46
Study: 16759902

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15320919

Group type: EXPERIMENTAL
Intervention: Funding to establish a school-based breakfast club
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breakfast club attendees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no funding)
Number of subjects: 0
Study: 11473139

Group type: EXPERIMENTAL
Intervention: Snapshot methods (same-day telephone interviews or one-off weekly diaries)
Number of subjects: 375

Group type: COMPARATOR
Intervention: 6 month diaries
Number of subjects: 375

Group type: COMPARATOR
Intervention: Participants attending hospital outpatient clinics
Number of subjects: 375
Study: 9409501

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: No oxygen therapy (Control)
Number of subjects: 50
Study: 7773823

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg in 20 ml NaCl)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 ml, 0.375%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (20 ml, control group)
Number of subjects: 40
Study: 2119878

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen
Number of subjects: 395

Group type: COMPARATOR
Intervention: Non-cisplatin-containing regimen
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine
Number of subjects: 395
Study: 344003

Group type: EXPERIMENTAL
Intervention: Desoximetasone emollient cream (0.25 percent)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Betamethasone valerate cream (0.1 percent)
Number of subjects: 1000
Study: 31733126

Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 374
Study: 28936902

Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 1942
Study: 28793995

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) 800-1000 kcal/d for 8 weeks
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Clinical changes during the LCD
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Baseline expression added to clinical changes model
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Clinical models for glycemic improvements
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Expression changes during the LCD added to clinical models
Number of subjects: 191
Study: 25460258

Group type: EXPERIMENTAL
Intervention: Psychoeducation about the mood-as-input hypothesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Befriending control group
Number of subjects: 0
Study: 24502231

Group type: EXPERIMENTAL
Intervention: Group-based physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Individual physiotherapy
Number of subjects: 30
Study: 22967016

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during high-dose chemotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no oral cryotherapy)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 78
Study: 20418097

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 246

Group type: COMPARATOR
Intervention: No cetuximab
Number of subjects: 246
Study: 16860921

Group type: EXPERIMENTAL
Intervention: High depressive symptoms group (CES-D*16)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low depressive symptoms group (CES-D < 16)
Number of subjects: 55
Study: 15616083

Group type: EXPERIMENTAL
Intervention: PCIA remifentanil (0.27‐0.93 microg/kg per bolus)
Number of subjects: 88

Group type: COMPARATOR
Intervention: IV infusion of meperidine (150 mg, range 75-200 mg)
Number of subjects: 88
Study: 11864867

Group type: EXPERIMENTAL
Intervention: Durnin-Womersley formula
Number of subjects: 54

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 54
Study: 10443885

Group type: EXPERIMENTAL
Intervention: Interferon-beta1a 22 microg (6 mIU)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Interferon-beta1a 44 microg (12 mIU)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Interferon-beta1a 22 microg (6 mIU) and 44 microg (12 mIU)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Initial monthly scanning cohort
Number of subjects: 560
Study: 8886295

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 1905799

Group type: EXPERIMENTAL
Intervention: Immediate treatment with oral penicillin V
Number of subjects: 306

Group type: COMPARATOR
Intervention: Delayed treatment with placebo followed by penicillin V
Number of subjects: 306
Study: 6342637

Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 100 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dihydrocodeine 60 mg
Number of subjects: 50
Study: 31907013

Group type: EXPERIMENTAL
Intervention: Informed Health Choices primary school resources (textbooks, exercise books, teachers' guide)
Number of subjects: 10813

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10813

Group type: EXPERIMENTAL
Intervention: Informed Health Choices primary school resources
Number of subjects: 10813
Study: 31094225

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 and bemarituzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: mFOLFOX6 and placebo
Number of subjects: 0
Study: 25733022

Group type: EXPERIMENTAL
Intervention: Depuy Discover artificial disc
Number of subjects: 153

Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion (ACDF) with iliac crest bone graft and plating
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Secondary surgery
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: EQ-5D and visual analog scale
Number of subjects: 153
Study: 23317960

Group type: EXPERIMENTAL
Intervention: 6-month thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy
Number of subjects: 551

Group type: COMPARATOR
Intervention: Extended treatment up to 9 months
Number of subjects: 551

Group type: COMPARATOR
Intervention: Observation without additional treatment
Number of subjects: 551
Study: 20852005

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Placebo
Number of subjects: 124
Study: 19243767

Group type: COMPARATOR
Intervention: NSAID (diclofenac sodium, 25 mg 3 times daily) and omeprazole (20 mg once daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PG (misoprostol, 200 microg 3 times daily) with NSAID and omeprazole
Number of subjects: 34
Study: 16739326

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (doxifluridine) at 800 mg/body daily for 3 years
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (doxifluridine) at 800 mg/body daily for 1 year
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Endocrine therapy with gosereline acetate (3.6 mg/body, monthly) for pre-menopausal patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Endocrine therapy with tamoxifen (20 mg/day, daily) for post-menopausal patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (doxifluridine)
Number of subjects: 87
Study: 14710214

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (EMP) and vinblastine (VBL) combination chemotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Estramustine phosphate (EMP) alone
Number of subjects: 92
Study: 11846062

Group type: EXPERIMENTAL
Intervention: Sequential high-dose methotrexate (1 g/m2, day 1), fluorouracil (1.5 g/m2, day 1), leucovorin (15 mg/m2, days 2-4), and doxorubicin (30 mg/m2, day 15), repeated at a 28-day interval, followed by radical surgery
Number of subjects: 20
Study: 1408299

Group type: EXPERIMENTAL
Intervention: Standard program with additional psychological components
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard inpatient rehabilitation program
Number of subjects: 45
Study: 3936558

Group type: EXPERIMENTAL
Intervention: Sustained-release formulations of valproic acid (VPA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard tablet of valproic acid (VPA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous (i.v.) preparation of valproic acid (VPA)
Number of subjects: 6
Study: 30257756

Group type: EXPERIMENTAL
Intervention: 3 PRP injections in the subacromial space at 1-week intervals
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single depot corticosteroid injection in the subacromial space
Number of subjects: 50
Study: 27280016

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study: 24991815

Group type: EXPERIMENTAL
Intervention: HIV-uninfected men (HIV‐)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HIV-infected men using HAART (HIV+/HAART+)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: HIV-infected men not using HAART (HIV+/HAART‐)
Number of subjects: 159

Group type: COMPARATOR
Intervention: HIV-infected men
Number of subjects: 159
Study: 23672220

Group type: EXPERIMENTAL
Intervention: Acarbose chewable tablet
Number of subjects: 234

Group type: COMPARATOR
Intervention: Acarbose treatment (control group)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study: 20354531

Group type: EXPERIMENTAL
Intervention: Chemoradiation (5-fluorouracil and mitomycin C)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 577
Study: 18279686

Group type: EXPERIMENTAL
Intervention: EE-betadex clathrate/drsp tablet
Number of subjects: 18

Group type: COMPARATOR
Intervention: EE/drsp tablet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Microcrystalline suspension
Number of subjects: 18
Study: 16178134

Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouthrinse (Crest Pro‐Health Rinse)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Cosmetic rinse control (Scope)
Number of subjects: 273
Study: 12826042

Group type: EXPERIMENTAL
Intervention: Aprepitant + dexamethasone + ondansetron on day 1 and aprepitant + dexamethasone on days 2-5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5)
Number of subjects: 0
Study: 10855533

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/l x kg(‐1) x min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 8841058

Group type: EXPERIMENTAL
Intervention: Intensive orthoptic screening by orthoptists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual non-specialist screening
Number of subjects: 0
Study: 2004541

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 400 micrograms once daily
Number of subjects: 248

Group type: COMPARATOR
Intervention: Intranasal budesonide 200 micrograms twice daily
Number of subjects: 248
Study: 4088460

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg)
Number of subjects: 0
Study: 31437413

Group type: EXPERIMENTAL
Intervention: Telephone-based peer support until 4 months postpartum
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional support
Number of subjects: 114
Study: 30107003

Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment with high pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment
Number of subjects: 0